Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics N.V (PRQR) Share-based Compensation: 2021-2025

Historic Share-based Compensation for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to $1.3 million.

  • ProQR Therapeutics N.V's Share-based Compensation rose 94.29% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year increase of 24.19%. This contributed to the annual value of $2.7 million for FY2024, which is 19.09% down from last year.
  • ProQR Therapeutics N.V's Share-based Compensation amounted to $1.3 million in Q3 2025, which was up 26.91% from $1.0 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's 5-year Share-based Compensation high stood at $2.0 million for Q4 2021, and its period low was -$394,836 during Q4 2022.
  • Its 3-year average for Share-based Compensation is $840,146, with a median of $799,562 in 2024.
  • As far as peak fluctuations go, ProQR Therapeutics N.V's Share-based Compensation crashed by 119.38% in 2022, and later spiked by 318.55% in 2023.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's Share-based Compensation stood at $2.0 million in 2021, then crashed by 119.38% to -$394,836 in 2022, then skyrocketed by 318.55% to $862,904 in 2023, then declined by 29.66% to $606,962 in 2024, then skyrocketed by 94.29% to $1.3 million in 2025.
  • Its Share-based Compensation stands at $1.3 million for Q3 2025, versus $1.0 million for Q2 2025 and $797,328 for Q1 2025.